Background: ROCKET AF and its East Asian subanalysis demonstrated that rivaroxaban
| INTRODUCTION
The prevalence of non-valvular atrial fibrillation (NVAF) is growing rapidly in Asia, and it is estimated that the number of patients with NVAF in Asia will be greater than the number in Europe and the USA combined by 2050. 1 Data from large clinical trials have clearly indicated differences in the benefit-risk profiles of Asian and Caucasian patients, particularly a higher overall risk of stroke, and greater stroke-related morbidity and mortality in Asian patients. [2] [3] [4] Although treatment with vitamin K antagonists (VKAs) has long been the mainstay of therapy in this setting, warfarin is under-prescribed in Asian countries; antiplatelet therapy is commonly prescribed instead. 4 As an alternative to VKAs, non-VKA oral anticoagulants (NOACs) could be prescribed in Asian patients with NVAF. The phase III ROCKET AF study showed that rivaroxaban was non-inferior to warfarin for stroke prevention in patients with NVAF, with a reduced incidence of hemorrhagic stroke and ICH compared with warfarin. 5 A subgroup analysis in East Asian patients showed similar efficacy and safety of rivaroxaban vs warfarin, 6 as did J-ROCKET AF, which assessed reduced-dose rivaroxaban (15 mg once daily [od] ) in Japanese patients with NVAF. 7 In 2013, the Asia Pacific Heart Rhythm Society (APHRS) added recommendations for the use of NOACs in patients with NVAF. 
| METHODS
XANAP was a prospective, observational cohort study in unselected patients with NVAF starting rivaroxaban treatment to prevent stroke or non-CNS SE. The study was part of the XANTUS program and, as such, the study protocol was aligned with that of XANTUS, which is published elsewhere. 10 
| Study population and data collection
All study sites were in 10 countries across the Asia-Pacific region: Hong Kong, Indonesia, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam. Eligible patients were adults (aged ≥18 years) with a diagnosis of NVAF who provided written informed consent to participate in the study and who started rivaroxaban treatment for the prevention of stroke or non-CNS SE in accordance with the country-specific drug approval. Participating investigators were asked to screen all patients with NVAF receiving pharmacological treatment for stroke prevention regardless of the prescribed treatment. This screening documentation occurred before eligible and consenting patients signed the informed consent forms and it was not permissible to collect any patient-related data from the remaining patients. Each patient was consecutively screened and documented in an anonymous patient log file. To reduce selection bias, enrollment was consecutive and no eligible patients were to be omitted.
| Medication and follow-up
The decision to treat with rivaroxaban was solely at the discretion of the treating physician. Label-recommended doses were prescribed in accordance with the country-specific drug approval. In Taiwan, the approved rivaroxaban dose is 15 or 20 mg od for patients with KIM ET AL.
| 419 creatinine clearance (CrCl) >50 mL/min, and 10 or 15 mg od for patients with CrCl 15-50 mL/min. 11 The approved doses of rivaroxaban in the other countries are similar to European label recommendations, ie, 20 mg od for patients with CrCl ≥50 mL/min and 15 mg od for patients with CrCl 15-49 mL/min. 12 Patients were followed up for 1 year or until 30 days after permanent discontinuation of rivaroxaban (if <1 year) and investigators were asked to collect data at approximately 3-month intervals.
| Study outcomes
The primary outcomes were related to the safety of rivaroxaban and recorded as treatment-emergent adverse events (AEs), serious AEs (SAEs), all-cause mortality and major bleeding events (defined using 
| Study governance
The study complied with the Declaration of Helsinki and was approved by the appropriate Health Authorities, the independent Ethics Committees and independent Review Boards as required. The study was conducted in accordance with Good Pharmacoepidemiological Practice. An independent academic steering committee oversaw the design, execution and conduct of the study; was responsible for manuscript development; had full access to all of the data; and approved all versions of the manuscript.
Data management and statistical analyses were overseen by the sponsor to keep within Good Clinical Practice standards. The lead statistician oversaw programming and validation of the statistical analyses.
| Statistical analysis
Descriptive statistical analyses were performed on the safety popula- 
| Outcomes
Overall, 1.2% (95% CI 0.8-1.7) of the cohort of 2273 patients had adjudicated treatment-emergent major bleeding events (primary | 421 outcome), and the incidence rate was 1.5 events/100 patient-years (95% CI 1.0-2.1). There were 4 fatalities (incidence rate: 0.2 events/ 100 patient-years; 95% CI 0.1-0.6) from adjudicated treatmentemergent major bleeding events. Incidence rates were 0.7 events/ 100 patient-years (95% CI 0. Forty-seven patients had adjudicated treatment-emergent symptomatic thromboembolic events (secondary outcome) and the incidence rate was 2.6 events/100 patient-years (95% CI 1.9-3.4).
The incidence rates (number of events/100 patient-years [95% CI])
for stroke (any), TIA, non-CNS SE, stroke/non-CNS SE and MI were 1.7 (1.2-2.5), 0.2 (0.1-0.6), 0.1 (0.0-0.4), 1.9 (1.3-2.6) and 0.5 (0.2-0.9), respectively ( Table 3) .
Rates of major bleeding events and stroke/non-CNS SE generally rose with increasing CHADS 2 and CHA 2 DS 2 -VASc scores (Figure 2A , B). No major bleeding events were recorded for patients with a CHA 2 DS 2 -VASc score of 0 or 1, compared with an incidence rate of 1.6 events/100 patient-years (95% CI 1.1-2.4) in patients with a score of ≥2. Similarly, there were no recorded incidents of stroke/ non-CNS SE in patients with a CHA 2 DS 2 -VASc score of 0 or 1, rising to an incidence rate of 0.7 events/100 patient-years (95% CI 0.1-2.6) in patients with a score of 2, and 3.3 events/100 patient-years (95% CI 1.6-6.1) in patients with scores of 6-9. The incidence of major bleeding increased with age, occurring at a rate of 1.1 events/ 100 patient-years (95% CI 0.6-1.9) in patients aged <75 years and Table 3 .
| Additional outcomes
In total, 116 patients (5.1%) had at least 1 interruption to rivaroxaban treatment, which was most commonly due to bleeding (31 patients) or surgery (26 patients). The median treatment interruption was 7 days (interquartile range: 3-23 days). The majority of patients (83.2%) had no unscheduled hospital or general practitioner visits because of the use of rivaroxaban. The majority of patients (60.6%)
reported to their physicians that they were either "very satisfied" or "satisfied" with rivaroxaban treatment; a further 26.1% of patients were "neutral", 6.9% were "unsatisfied", 0.8% were "very unsatisfied"
and data were missing for 5.5%.
| DISCUSSION
The XANAP study provides insights into the routine clinical use of rivaroxaban in Asian patients with NVAF. XANAP is the first prospective, observational study to describe rivaroxaban use in a broad, real-world patient population with NVAF in 10 countries of the Asia-Pacific region. Findings are broadly consistent when cautiously compared with those of the observational sister study (XAN-TUS) in Europe, Canada and Israel, 9 and with the subanalysis of East Asian patients in the phase III ROCKET AF study, 6 taking into consideration differences in baseline characteristics. In XANAP, rivaroxaban demonstrated relatively low rates of stroke/non-CNS SE and low rates of major bleeding, including intracranial and GI bleeding.
Over 96% of patients with a mean CHADS 2 score of 2.3 receiving rivaroxaban did not experience any of the outcomes of stroke/non-CNS SE, treatment-emergent major bleeding or all-cause death.
The profile of the patient population in XANAP was substantially different from that in XANTUS (Table 4) . 9 Differences included a higher proportion of patients with prior stroke/non-CNS SE/TIA, lower mean weight (although weight data were unavailable for 28% of XANAP patients), a higher proportion of patients with moderate 4 Based on these scores, NVAF can be calculated to raise the relative risk of stroke fivefold in Caucasian populations, compared with a more modest increase in risk of 2.8-3.7-fold, depending on the Asian population studied. 4 Finally, persistence at 1 year was lower in XANAP compared with XANTUS (66% vs 80%; Table 4 ). It is of note that this result is consistent with the treatment persistence reported in a recent large retrospective database analysis of US patients treated with rivaroxaban for stroke prevention (N = 10 878; 60.1% persistence to rivaroxaban therapy at 1 year). 13 However, it should be pointed out that the US patient population in this analysis was enrolled in a different healthcare system to those countries in the XANAP studies. 13 The lower persistence in XANAP vs XANTUS may reflect lower medication adherence in developing countries, which were highly represented in XANAP. 14 
hospital prescription. Taken together, these differences indicate that the Asian population in XANAP was at higher risk of stroke and bleeding than the European and Canadian population in XANTUS, which is consistent with the observed higher incidence of hemorrhagic stroke and ICH in Asian patients. 4 Further comparisons show that XANAP patients were at lower risk of these outcomes than patients in the ROCKET AF East Asian subanalysis 6 and J-ROCKET, 7 with CHADS 2 scores of 2.3 vs 3.2 and 3.3, respectively (CHA 2 DS 2 -VASc score of 3.7 in XANAP, vs 4.4 in the ROCKET AF East Asian subanalysis; Table 4 ).
Overall rates of major bleeding, including major GI bleeding, were lower in patients in XANAP than observed in XANTUS, the ROCKET AF East Asian subanalysis and J-ROCKET (Table 4) . 6, 9 The reason for the lower rates of bleeding in XANAP is not completely understood. It is unlikely to simply be a result of the higher proportion of patients in XANAP receiving rivaroxaban 15 mg od, as the findings are consistent with the lower overall bleeding rates observed in rivaroxaban-treated patients in ROCKET AF from East Asia 6 and China, 15 compared with patients outside these regions.
However, rates of ICH were higher in XANAP compared with XAN-TUS, but similar to those in the ROCKET AF East Asian subanalysis.
This concurs with previously observed higher rates of ICH in Asian populations, 16, 17 which are thought to be because of increased cerebral microbleeds in Asian patients 4 and can be affected by extremes in body mass index and specific apolipoprotein alleles. 16 By contrast, fatal bleeding rates in XANAP were similar to those in XANTUS, the ROCKET AF East Asian subanalysis and J-ROCKET (Table 4) . 6, 9 The rates of stroke/non-CNS SE in XANAP were higher than those in XANTUS, but lower than those observed in the ROCKET AF East Asian subanalysis; this was consistent with the higher stroke risk and proportion of patients with prior stroke/SE/TIA involved in the ROCKET AF East Asian subanalysis (65%, vs 19% in XANAP; Table 4 ). Stroke is noted in the literature as being a particular risk for Asian patients with NVAF compared with their Caucasian counterparts. 4, [18] [19] [20] ) mean that the majority of the Taiwanese patients with CrCl ≥50 mL/min receiving the 15 mg dose were on label. It is also possible that physicians prescribed reduced rivaroxaban 15 mg od to patients with a higher co-morbidity burden who were more at risk of AEs; in XANTUS, rates of major outcomes were worse in patients receiving the reduced rivaroxaban dose. 9 However, it is also of note that the rivaroxaban 15 mg od dose was not The primary outcome for ROCKET AF, ROCKET AF East Asian subanalysis and J-ROCKET AF was the composite of stroke (ischemic and hemorrhagic) and SE. Bleeding outcomes in the safety, on-treatment population (n = 639), efficacy outcomes in the per protocol, on treatment population (n = 637). f Bleeding outcomes in the safety, on-treatment population (n = 466), efficacy outcomes in the intention-to-treat population (n = 468). The primary outcomes for XANTUS and XANAP were related to the safety of rivaroxaban and recorded as treatment-emergent AEs and SAEs, all-cause mortality and major bleeding events (defined using International Society on Thrombosis and Haemostasis criteria). | 425 associated with higher stroke/SE rates than warfarin in Japanese patients enrolled in the J-ROCKET AF trial or in patients included in a large retrospective Danish registry analysis. 21, 22 Another possible contributor to the higher stroke/SE rate in XANAP was the lower rate of persistence observed in XANAP compared with XANTUS (66% vs 80%), because breaks in anticoagulation could leave patients with NVAF at higher risk of stroke. Of note, the incidence rate of stroke/non-CNS SE in XANAP of 1.9 events/100 patient-years is lower than that reported in a recent retrospective cohort study of 
| Limitations
XANAP was a real-world, single-arm study and, as with any open-label study, the study design can introduce bias related to knowledge about treatment. Moreover, interference with patient management was not allowed because of the non-interventional nature of the study. In particular, this resulted in a relatively high proportion of patients (48.5%) with missing renal function data, similar to observations in the XAN-TUS study (in which CrCl measurements were unavailable for 34.4% of patients). 9 Because of the observational nature of the study, it is possible that CrCl was measured but not documented by the prescribing physician for some patients, which would have contributed to the missing data. Additionally, because rivaroxaban prescription was at the discretion of the treating physician, and a relatively important proportion of CrCl data were missing, some patients may not have received the label-recommended dose of rivaroxaban.
| CONCLUSIONS
XANAP is the first real-world, prospective, observational study to describe rivaroxaban use in a broad patient population with NVAF in 10 countries of the Asia-Pacific region. XANAP had low rates of stroke/non-CNS SE and major bleeding, including GI and fatal bleeding. When taking differences in baseline risk factors into consideration, findings were consistent with XANTUS and the phase III ROCKET AF study and the subsequent subanalysis in East Asian patients. This is particularly relevant in terms of CHADS 2 and CHA 2 DS 2 -VASc scores, which were similar to those in XANTUS, but lower than those in the ROCKET AF East Asian subanalysis.
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